VSTM250516C12000
- 0.00
- 0.000.00%
Verastem Newsroom
Verastem Oncology Receives FDA Clearance for Investigational New Drug Application for Cancer Treatment
Verastem Announces U.S. IND Clearance of VS-7375
Express News | Verastem Inc - Phase 1/2a Trial in U.S. to Start Mid-2025
Express News | Verastem Oncology Announces U.S. Ind Clearance of Vs-7375, Oral Kras G12D (on/off) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors
9 Health Care Stocks With Whale Alerts In Today's Session
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Jefferies Initiates Verastem(VSTM.US) With Buy Rating, Announces Target Price $15
Express News | Verastem Inc : Jefferies Initiates Coverage With Buy Rating; Price Target $15
Verastem Is Maintained at Outperform by Mizuho
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $8
Express News | Verastem Inc : Mizuho Cuts Target Price to $8 From $9
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem Oncology Reports Progress in Cancer Treatments
New Analyst Forecast: $VSTM Given $14.0 Price Target
Citi Maintains Verastem(VSTM.US) With Buy Rating, Raises Target Price to $10
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $9
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Raises Target Price to $10
Verastem Is Maintained at Buy by Guggenheim
Verastem Price Target Raised to $14.00/Share From $13.00 by Guggenheim
HC Wainwright & Co. Maintains Buy on Verastem, Raises Price Target to $10